Kissei Pharmaceutical Co Ltd (JP:4547)
:4547
Want to see JP:4547 full AI Analyst Report?
Top Page
Kissei Pharmaceutical Co
(4547)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥3,895.00
▼(-15.51% Downside)
Action:Reiterated
Date:05/12/26
The score is primarily supported by strong balance-sheet safety, but is held back by inconsistent/negative cash flow and weakening operating performance. Technical indicators also reflect a clear near-term downtrend, while valuation and dividend yield offer modest support.
Positive Factors
Balance sheet strength / low leverage
Very low debt and a conservative capital structure provide durable financial flexibility. This allows Kissei to fund R&D, absorb earnings volatility, pursue collaborations or milestone-funded programs, and withstand shocks without forcing distress financing, supporting multi-month resilience.
Negative Factors
Weak and volatile cash generation
Inconsistent operating and free cash flow undermines the firm's ability to self-fund R&D, capex, or dividend policies sustainably. Persistent negative cash years increase reliance on external financing or milestone payments and limit the company's ability to convert accounting profits into durable liquidity.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength / low leverage
Very low debt and a conservative capital structure provide durable financial flexibility. This allows Kissei to fund R&D, absorb earnings volatility, pursue collaborations or milestone-funded programs, and withstand shocks without forcing distress financing, supporting multi-month resilience.
Read all positive factors
Kissei Pharmaceutical Co (4547) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥153.38B
Dividend Yield2.48%
Average Volume (3M)67.88K
Price to Earnings (P/E)11.5
Beta (1Y)0.45
Revenue Growth10.28%
EPS Growth20.78%
CountryJP
Employees1,779
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)289.63
Shares Outstanding46,541,985
10 Day Avg. Volume76,260
30 Day Avg. Volume67,883
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.84
Price to Sales (P/S)1.98
P/FCF Ratio-30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,220.00Price Target Upside-8.46% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)287.66
Revenue Forecast (FY)¥95.99B
Kissei Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for ...
How the Company Makes Money
Kissei primarily makes money by selling prescription pharmaceuticals, generating revenue from product sales to medical institutions and via pharmaceutical distribution channels in its core market (primarily Japan). A second revenue stream comes fr...
Kissei Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
88
Very Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 89.36B | 97.41B | 88.33B | 75.58B | 67.49B | 65.38B |
| Gross Profit | 44.26B | 45.82B | 44.06B | 37.34B | 32.38B | 31.24B |
| EBITDA | 20.37B | 1.72B | 20.25B | 18.72B | 17.81B | 20.26B |
| Net Income | 12.37B | 13.78B | 11.96B | 11.16B | 10.53B | 12.92B |
Balance Sheet | ||||||
| Total Assets | 243.67B | 275.09B | 244.06B | 260.93B | 221.20B | 238.09B |
| Cash, Cash Equivalents and Short-Term Investments | 48.75B | 54.42B | 48.65B | 45.93B | 49.60B | 53.15B |
| Total Debt | 1.77B | 1.25B | 1.60B | 1.73B | 1.95B | 1.98B |
| Total Liabilities | 35.43B | 43.55B | 33.93B | 39.79B | 26.38B | 35.91B |
| Stockholders Equity | 207.09B | 230.15B | 209.00B | 220.03B | 193.90B | 201.39B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -6.37B | 2.01B | -2.88B | -8.78B | 44.00M |
| Operating Cash Flow | 0.00 | -1.49B | 6.52B | -1.68B | -6.68B | 1.53B |
| Investing Cash Flow | 0.00 | 17.50B | 4.95B | 8.69B | 6.00B | 10.78B |
| Financing Cash Flow | 0.00 | -10.26B | -9.32B | -10.01B | -3.42B | -2.76B |
Kissei Pharmaceutical Co Technical Analysis
Negative
4610.00
Price Trends
4399.29
Negative
4483.24
Negative
4370.58
Negative
Market Momentum
-184.93
Positive
33.65
Neutral
20.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4547, the sentiment is Negative. The current price of 4610 is above the 20-day moving average (MA) of 4022.75, above the 50-day MA of 4399.29, and above the 200-day MA of 4370.58, indicating a bearish trend. The MACD of -184.93 indicates Positive momentum. The RSI at 33.65 is Neutral, neither overbought nor oversold. The STOCH value of 20.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4547.
Kissei Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥107.36B | 14.33 | 4.81% | 2.34% | 11.21% | 39.02% | |
58 Neutral | ¥153.38B | 11.47 | 6.70% | 2.48% | 10.28% | 20.78% | |
55 Neutral | ¥171.04B | 18.98 | ― | 2.28% | 6.69% | 6.72% | |
54 Neutral | ¥60.85B | 19.33 | ― | 3.36% | -2.94% | -62.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥136.33B | 67.59 | -2.58% | 4.16% | -18.25% | -84.71% | |
48 Neutral | ¥186.03B | 34.83 | 12.02% | 2.14% | 5.44% | -72.35% |
* Healthcare Sector Average
JP:4547
Kissei Pharmaceutical Co
3,745.00
-282.38
-7.01%
JP:4521
Kaken Pharmaceutical Co
3,765.00
155.58
4.31%
JP:4553
Towa Pharmaceutical Co
3,715.00
660.96
21.64%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,145.00
245.74
8.48%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,129.00
-309.12
-21.49%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,717.00
4.41
0.26%
Kissei Pharmaceutical Co Corporate Events
Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
Jun 3, 2026
Kissei Pharmaceutical reported that, during the period from May 12 to May 31, 2026, it did not repurchase any of its own common shares under a previously authorized buyback program. The company had obtained board approval in May to buy back up to ...
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
May 27, 2026
Kissei Pharmaceutical has filed a new drug application in Japan for olutasidenib, a targeted therapy for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, seeking approval to manufacture and market the drug domestical...
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
May 21, 2026
Kissei Pharmaceutical has revised the Japanese package insert for its rare-disease drug TAVNEOS to highlight the risk of serious hepatic dysfunction, including vanishing bile duct syndrome and reported fatal cases. The update, prompted by Ministry...
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
May 15, 2026
Kissei Pharmaceutical has begun an information campaign urging Japanese healthcare professionals to avoid starting new patients on TAVNEOS and to reassess ongoing treatments, after U.S. and European regulators raised serious concerns over the drug...
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
May 12, 2026
Kissei Pharmaceutical reported record-high consolidated revenue for the fiscal year ended March 31, 2026, with net sales rising 10.3% year on year to ¥97.4 billion, driven by 3.5% growth in its pharmaceutical business and a 49.3% surge in oth...
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
May 11, 2026
Kissei Pharmaceutical’s board has approved a share buyback of up to 1.3 million common shares, representing 3.14% of its outstanding stock, for a maximum of 6 billion yen. The repurchases will run from May 12 to December 31, 2026, via market...
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
May 11, 2026
Kissei Pharmaceutical Co. released supplementary explanatory materials for its financial results for the fiscal year ended March 31, 2026, outlining key elements such as consolidated income statements, balance sheets and cash flow statements. The ...
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
May 11, 2026
Kissei Pharmaceutical reported fiscal 2026 net sales of ¥97.4 billion, up 10.3% year on year, but swung to an operating loss of ¥2.9 billion and an ordinary loss of ¥1.2 billion, while profit attributable to owners of parent rose 15...
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
May 1, 2026
Kissei Pharmaceutical has signed a sublicense agreement with Taiwan-based Orient EuroPharma to develop and commercialize the acute myeloid leukemia drug olutasidenib in Taiwan, building on their existing collaboration around diabetes drug Glufast....
Kissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
Apr 24, 2026
Kissei Pharmaceutical has appointed Keiji Miyazawa as its new President and COO, effective June 23, 2026, pending approval at the regular shareholders’ and board meetings. Miyazawa, currently a board member and head of the Research Division ...
Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio
Mar 19, 2026
Kissei Pharmaceutical has launched Yselty tablets 100mg, an orally administered GnRH antagonist (linzagolix choline), in Japan for the treatment of symptoms caused by uterine fibroids, such as heavy menstrual bleeding, pain and anemia. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.